JP5560202B2 - Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 - Google Patents

Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 Download PDF

Info

Publication number
JP5560202B2
JP5560202B2 JP2010540047A JP2010540047A JP5560202B2 JP 5560202 B2 JP5560202 B2 JP 5560202B2 JP 2010540047 A JP2010540047 A JP 2010540047A JP 2010540047 A JP2010540047 A JP 2010540047A JP 5560202 B2 JP5560202 B2 JP 5560202B2
Authority
JP
Japan
Prior art keywords
phenyl
pyrazole
amino
carbonyl
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010540047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507916A5 (cg-RX-API-DMAC7.html
JP2011507916A (ja
Inventor
マルク・ナツァレ
ゲーアノト・ツェッヒ
ヨッヘン・ゲルリッツァー
メリッタ・ユースト
チロ・ヴァイス
ゲーアハルト・ヘスラー
ヴェルンガルト・チェフティツキ
スフェン・ルーフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2011507916A publication Critical patent/JP2011507916A/ja
Publication of JP2011507916A5 publication Critical patent/JP2011507916A5/ja
Application granted granted Critical
Publication of JP5560202B2 publication Critical patent/JP5560202B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010540047A 2007-12-26 2008-12-12 Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 Expired - Fee Related JP5560202B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291628.1 2007-12-26
EP07291628 2007-12-26
PCT/EP2008/010573 WO2009080227A2 (en) 2007-12-26 2008-12-12 Pyrazole-carboxamide derivatives as p2y12 antagonists

Publications (3)

Publication Number Publication Date
JP2011507916A JP2011507916A (ja) 2011-03-10
JP2011507916A5 JP2011507916A5 (cg-RX-API-DMAC7.html) 2012-02-02
JP5560202B2 true JP5560202B2 (ja) 2014-07-23

Family

ID=39495287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010540047A Expired - Fee Related JP5560202B2 (ja) 2007-12-26 2008-12-12 Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体

Country Status (4)

Country Link
US (1) US8598179B2 (cg-RX-API-DMAC7.html)
EP (1) EP2238127B1 (cg-RX-API-DMAC7.html)
JP (1) JP5560202B2 (cg-RX-API-DMAC7.html)
WO (1) WO2009080227A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI361690B (en) 2007-11-29 2012-04-11 Actelion Pharmaceuticals Ltd Phosphonic acid derivatives
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
RU2011144763A (ru) 2009-04-08 2013-05-20 Актелион Фармасьютиклз Лтд 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины
NZ596388A (en) 2009-04-22 2013-05-31 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
UY33200A (es) 2010-01-26 2011-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
AR085013A1 (es) 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
EP2736891B1 (en) 2011-07-26 2016-04-20 Sanofi Substituted 3-(thiazole-4-carbonyl)- or 3-(thiazole-2-carbonyl)- aminopropionic acid derivatives and their use as pharmaceuticals
CN105646362B (zh) 2011-07-26 2019-07-05 赛诺菲 3-杂芳酰基氨基-丙酸衍生物及其作为药物的用途
US9539246B2 (en) 2011-08-30 2017-01-10 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013072327A1 (en) 2011-11-14 2013-05-23 Sanofi Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
JP2015521183A (ja) * 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
CA2871542A1 (en) 2012-05-18 2013-11-21 Sanofi Pyrazole derivatives and their use as lpar5 antagonists
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2725025A1 (fr) * 2012-10-26 2014-04-30 Sanofi Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12
JP6357529B2 (ja) 2013-03-28 2018-07-11 サノフイ ビアリール−プロピオン酸誘導体および医薬品としてのその使用
KR20150136507A (ko) 2013-03-28 2015-12-07 사노피 바이아릴-프로피온산 유도체 및 약제로서의 그의 용도
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CN104418938B (zh) * 2013-08-28 2018-05-18 北京赛而生物药业有限公司 一种抗凝血化合物、其制备方法和用途、及包含其的药物组合物
CN103626630B (zh) * 2013-11-15 2015-08-19 深圳致君制药有限公司 利伐沙班中间体及其制备方法
US9231217B2 (en) * 2013-11-28 2016-01-05 Semiconductor Energy Laboratory Co., Ltd. Synthesis method of organometallic complex, synthesis method of pyrazine derivative, 5,6-diaryl-2-pyrazyl triflate, light-emitting element, light-emitting device, electronic device, and lighting device
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
EP3595666A1 (en) 2017-03-15 2020-01-22 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
CN110204541B (zh) * 2018-02-28 2020-06-23 新发药业有限公司 一种阿哌沙班的制备方法
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
CN112778184B (zh) * 2021-01-29 2022-05-17 绍兴文理学院 一种叔胺α位的芳基化方法
CN119930579A (zh) * 2025-01-15 2025-05-06 四川轻化工大学 哌啶环类化合物及其合成方法、药学上可接受的盐与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
WO2003066671A1 (en) 2002-02-05 2003-08-14 Dainippon Pharmaceutical Co., Ltd. Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof
WO2004056815A1 (en) * 2002-12-23 2004-07-08 Aventis Pharma Deutschland Gmbh PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
AU2003249865A1 (en) 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7029587B2 (en) 2004-04-02 2006-04-18 Lynntech, Inc. Water purification
FR2884666B1 (fr) 2005-04-19 2007-06-22 Thales Sa Procede et dispositif de determination d'une adresse au sein d'un reseau aeronautique de telecommunication
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
WO2009080227A2 (en) 2009-07-02
JP2011507916A (ja) 2011-03-10
US20110039829A1 (en) 2011-02-17
US8598179B2 (en) 2013-12-03
EP2238127B1 (en) 2012-08-15
WO2009080227A3 (en) 2009-09-17
EP2238127A2 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
JP5560202B2 (ja) Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
JP5504171B2 (ja) Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
US8669266B2 (en) Quinoline-carboxamide derivatives as P2Y12 antagonists
JP4709763B2 (ja) 第Ｘａ因子阻害剤としてのインダゾール誘導体
JP4585448B2 (ja) 第Ｘａ因子阻害剤としてのピラゾール−誘導体
JP2007535497A (ja) 第Ｘａ因子阻害剤としてのβ−アミノ酸誘導体
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
JP4658940B2 (ja) 第Ｘａ因子阻害剤としてのベンゾイミダゾール誘導体
JP5422569B2 (ja) 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
JP4733642B2 (ja) 第Ｘａ因子阻害剤としてのアザインドール−誘導体
KR101373533B1 (ko) 인자 Ｘａ 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
KR20060136457A (ko) 인자 Ｘａ 억제제로서의 피롤-유도체
HK1141803B (en) Quinoline-carboxamide derivatives as p2y12 antagonists
MXPA06008712A (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140609

R150 Certificate of patent or registration of utility model

Ref document number: 5560202

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees